for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

第一三共株式会社

4568.T

現在値

9,324.00JPY

変化

115.00(+1.25%)

出来高

1,181,200

本日のレンジ

9,151.00

 - 

9,324.00

52週レンジ

5,193.00

 - 

10,085.00

∙ 約20分前の相場を表示しています。

適時開示

AstraZeneca Enters Collaboration In Oncology With Daiichi

July 27 (Reuters) - AstraZeneca Plc <AZN.L>::ASTRAZENECA ENTERS COLLABORATION IN ONCOLOGY.ASTRAZENECA AND DAIICHI SANKYO ENTER COLLABORATION TO DEVELOP AND COMMERCIALISE NEW ANTIBODY DRUG CONJUGATE.POTENTIAL NEW MEDICINE DS-1062 COULD REDEFINE TREATMENT STANDARDS IN LUNG, BREAST AND MULTIPLE OTHER CANCERS.ASTRAZENECA WILL PAY DAIICHI SANKYO AN UPFRONT PAYMENT OF $1 BLN IN STAGED PAYMENT.POTENTIAL NEW MEDICINE DS-1062 COULD REDEFINE TREATMENT STANDARDS IN LUNG, BREAST AND MULTIPLE OTHER CANCERS.TO PAY CONDITIONAL AMOUNTS OF UP TO $1BN FOR SUCCESSFUL ACHIEVEMENT OF REGULATORY APPROVALS AND UP TO $4BN FOR SALES-RELATED MILESTONES .TRANSACTION DOES NOT IMPACT COMPANY'S FINANCIAL GUIDANCE FOR 2020 .THERE ARE NO CLOSING CONDITIONS TO TRANSACTION.TRANSACTION WILL BE ACCOUNTED FOR AS AN INTANGIBLE ASSET ACQUISITION.DS-1062 IS CURRENTLY IN DEVELOPMENT FOR TREATMENT OF MULTIPLE TUMOURS THAT COMMONLY EXPRESS CELL-SURFACE GLYCOPROTEIN TROP2.

Daiichi Sankyo Initiates Clinical Trial With In Collaboration With Sarah Cannon Research Institute

May 22 (Reuters) - Daiichi Sankyo Co Ltd <4568.T>::DAIICHI SANKYO INITIATES CLINICAL TRIAL WITH 5TH DXD ADC, DS-6157, IN COLLABORATION WITH SARAH CANNON RESEARCH INSTITUTE.

Astrazeneca Says Enhertu Designated Gastric Cancer Breakthrough Therapy Designation

May 11 (Reuters) - AstraZeneca Plc <AZN.L>::ASTRAZENECA PLC - ENHERTU DESIGNATED GASTRIC CANCER BTD.ASTRAZENECA - ENHERTU GRANTED BREAKTHROUGH THERAPY DESIGNATION IN US FOR HER2-POSITIVE METASTATIC GASTRIC CANCER.ASTRAZENECA - ENHERTU GRANTED BTD IN GASTRIC CANCER PATIENTS WHO HAVE RECEIVED TWO OR MORE PRIOR REGIMENS INCLUDING TRASTUZUMAB.

Daiichi Sankyo Co Ltd - Announces 3-For-1 Share Split On Sept. 30

April 27 (Reuters) - Daiichi Sankyo Co Ltd <4568.T>::DAIICHI SANKYO CO LTD - ANNOUNCES 3-FOR-1 SHARE SPLIT ON SEPT. 30.

AstraZeneca CEO says not seen operational disruption in China

Feb 14 (Reuters) - AstraZeneca PLC <AZN.L>::ASTRAZENECA CEO SAYS OVERALL HAVE NOT SEEN DISRUPTION IN OPERATIONS IN CHINA - CONF CALL.ASTRAZENECA CEO SAYS HAS SEEN MINIMAL IMPACT ON CLINICAL TRIALS IN CHINA FOLLOWING THE CORONAVIRUS OUTBREAK - CONF CALL.ASTRAZENECA SAYS INITIAL INDICATORS FOR BREAST CANCER DRUG ENHERTU ARE POSITIVE - CONF CALL.ASTRAZENECA CFO SAYS CO REMAINS INTERESTED IN IMMEDIATELY ACCRETIVE DEALS - CONF CALL.

AstraZeneca Says 2020 Rev Growth To Depend On Impact Of Coronavirus

Feb 14 (Reuters) - AstraZeneca PLC <AZN.L>::ASTRAZENECA PLC - AZN: FULL-YEAR AND Q4 2019 RESULTS.ASTRAZENECA - ALL GUIDANCE ASSUMES UNFAVOURABLE IMPACT FROM CHINA LASTING UP TO A FEW MONTHS AS A RESULT OF RECENT NOVEL CORONAVIRUS OUTBREAK.ASTRAZENECA PLC - COMPANY WILL MONITOR CLOSELY DEVELOPMENT OF EPIDEMIC AND ANTICIPATES PROVIDING AN UPDATE AT TIME OF Q1 2020 RESULTS..ASTRAZENECA - WILL MONITOR CLOSELY DEVELOPMENT OF CORONAVIRUS EPIDEMIC AND ANTICIPATES PROVIDING AN UPDATE AT TIME OF Q1 2020 RESULTS.ASTRAZENECA - DEPENDING ON IMPACT OF COVID-19 EPIDEMIC, REVENUE EXPECTED TO INCREASE BY A HIGH SINGLE-DIGIT TO LOW DOUBLE-DIGIT PERCENTAGE FOR 2020.ASTRAZENECA PLC QTRLY TOTAL REVENUE $6,664 MILLION VERSUS $6,417 MILLION AS REPORTED A YEAR EARLIER.ASTRAZENECA PLC - QTRLY REPORTED EARNINGS PER SHARE $0.24.ASTRAZENECA PLC - QTRLY CORE EARNINGS PER SHARE $0.89.ASTRAZENECA PLC - SEES 2020 CORE EPS IS EXPECTED TO INCREASE BY A MID- TO HIGH-TEENS PERCENTAGE.ASTRAZENECA PLC - SECOND INTERIM DIVIDEND OF $1.90 PER SHARE HAS BEEN DECLARED.ASTRAZENECA PLC - BOARD HAS REAFFIRMED ITS COMMITMENT TO PROGRESSIVE DIVIDEND POLICY.ASTRAZENECA PLC - SEES 2020 CAPITAL EXPENDITURE IS EXPECTED TO BE BROADLY STABLE VERSUS PRIOR YEAR.ASTRAZENECA PLC QTRLY TAGRISSO SALES $884 MILLION VERSUS $594 MILLION AS REPORTED A YEAR EARLIER.ASTRAZENECA PLC QTRLY LYNPARZA SALES $351 MILLION VERSUS $209 MILLION AS REPORTED A YEAR EARLIER.

Immunic Exercises Its Option For The Exclusive Worldwide License To IMU-856 From Daiichi Sankyo Co Ltd

Jan 8 (Reuters) - Immunic Inc <IMUX.O>::IMMUNIC EXERCISES ITS OPTION FOR THE EXCLUSIVE WORLDWIDE LICENSE TO IMU-856 FROM DAIICHI SANKYO CO., LTD..IMMUNIC INC - INTENDS TO BEGIN PHASE 1 CLINICAL STUDIES FOR GROUP OF COMPOUNDS, DESIGNATED BY IMMUNIC AS IMU-856, IN H1 2020.IMMUNIC - FINANCIAL TERMS OF AGREEMENT HAVE NOT BEEN DISCLOSED.IMMUNIC - OPTION & LICENSE AGREEMENT GIVES CO EXCLUSIVE RIGHTS TO COMMERCIALIZATION OF IMU-856 IN ALL COUNTRIES, INCLUDING U.S., EUROPE AND JAPAN.IMMUNIC - OPTION AGREEMENT ALSO INCLUDES EXCLUSIVITY ON A PATENT APPLICATION FILED BY DAIICHI SANKYO, COVERING IMU-856'S COMPOSITION OF MATTER.IMMUNIC - CONCURRENT WITH OPTION EXERCISE, IMMUNIC WILL PAY TO DAIICHI SANKYO A ONE-TIME UPFRONT LICENSING FEE.

AstraZeneca Says Enhertu (Trastuzumab Deruxtecan) Approved In U.S.

Dec 23 (Reuters) - AstraZeneca PLC <AZN.L>::ASTRAZENECA PLC - ENHERTU (TRASTUZUMAB DERUXTECAN) APPROVED IN US.

FDA Approves New Treatment Option For Patients With Her2-Positive Breast Cancer Who Have Progressed On Available Therapies

Dec 20 (Reuters) - FDA: :FDA APPROVES NEW TREATMENT OPTION FOR PATIENTS WITH HER2-POSITIVE BREAST CANCER WHO HAVE PROGRESSED ON AVAILABLE THERAPIES.FDA - GRANTED THE APPROVAL OF ENHERTU TO DAIICHI SANKYO.FDA - PRESCRIBING INFO FOR ENHERTU INCLUDES BOXED WARNING TO ADVISE HEALTH CARE PROFESSIONALS, PATIENTS ABOUT RISK OF INTERSTITIAL LUNG DISEASE.FDA - PRESCRIBING INFO FOR ENHERTU INCLUDES BOXED WARNING TO ADVISE HEALTH CARE PROFESSIONALS, PATIENTS ABOUT RISK OF EMBRYO-FETAL TOXICITY.FDA - INTERSTITIAL LUNG DISEASE AND PNEUMONITIS, INCLUDING CASES RESULTING IN DEATH, HAVE BEEN REPORTED WITH ENHERTU.

Exelixis Says Daiichi Sankyo Announced Positive Results From Phase 3 Pivotal Trial Of Esaxerenone

Nov 7 (Reuters) - Exelixis Inc <EXEL.O>::EXELIXIS’ COLLABORATOR DAIICHI SANKYO ANNOUNCES POSITIVE RESULTS FROM PHASE 3 PIVOTAL TRIAL OF ESAXERENONE IN PATIENTS WITH DIABETIC NEPHROPATHY.ESAXERENONE HAS BEEN APPROVED AS A TREATMENT FOR PATIENTS WITH HYPERTENSION IN JAPAN, WHERE IT IS MARKETED AS MINNEBRO TABLETS.DAIICHI SANKYO IS SOLELY RESPONSIBLE FOR ESAXERENONE'S DEVELOPMENT AND COMMERCIALIZATION.PRIMARY ENDPOINT OF STUDY IS RATE OF REMISSION OF MICROALBUMINURIA AFTER 52-WEEK TREATMENT.EXELIXIS -FOR ESAXERENONE, CO ELIGIBLE FOR SUBSTANTIAL COMMERCIALIZATION MILESTONES, LOW DOUBLE-DIGIT ROYALTIES ON SALES, AS IT ADVANCES.STUDY SHOWED THAT ESAXERENONE-BASED REGIMEN RESULTED IN A SIGNIFICANTLY HIGHER UACR REMISSION RATE AS COMPARED TO PLACEBO.

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up